Skip to content

Study · Animal study (in vivo) · rat · 2016

6 results

Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats.

Yu J, Morimoto K, Bao W, Yu Z, Okita Y, Okada K

Surgery today13 Dec 2015Cited by 29 (Europe PMC)

PMID26658813 (opens in a new tab)DOI10.1007/s00595-015-1287-z (opens in a new tab)PepBankPUB-26658813
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with aneurysms, lixisenatide significantly decreased aneurysm-wall reactive oxygen species on day 14.

    In plain wordsIn rats with aneurysms, lixisenatide decreased reactive oxygen species in the aneurysm walls.

    Peptide
    Lixisenatide
    Outcome
    DecreaseReactive oxygen species on day 14
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    On day 14, ROS expression and 8-OHdG-positive cells in the aneurysm walls were seen to have been significantly decreased by lixisenatide treatment.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with aneurysms, lixisenatide significantly decreased aneurysm-wall 8-OHdG-positive cells on day 14.

    In plain wordsIn rats with aneurysms, lixisenatide decreased cells with a marker of DNA oxidation in the aneurysm walls.

    Peptide
    Lixisenatide
    Outcome
    Decrease8-OHdG-positive cells on day 14
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    On day 14, ROS expression and 8-OHdG-positive cells in the aneurysm walls were seen to have been significantly decreased by lixisenatide treatment.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with aneurysms, lixisenatide decreased ERK expression.

    In plain wordsIn rats with aneurysms, lixisenatide decreased ERK expression.

    Peptide
    Lixisenatide
    Outcome
    DecreaseERK expression
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    Western blot analysis showed decreased ERK expression.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with aneurysms, lixisenatide significantly reduced tumor necrosis factor-α mRNA in aneurysm walls.

    In plain wordsIn rats with aneurysms, lixisenatide reduced an inflammatory gene's expression in the aneurysm walls.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTumor necrosis factor-α mRNA
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    There was significantly reduced tumor necrosis factor-α mRNA expression in the aneurysm walls and CD68-positive cell infiltration in the aneurysm walls.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with aneurysms, lixisenatide significantly reduced CD68-positive cell infiltration in aneurysm walls.

    In plain wordsIn rats with aneurysms, lixisenatide reduced CD68-positive cell infiltration in the aneurysm walls.

    Peptide
    Lixisenatide
    Outcome
    DecreaseCD68-positive cell infiltration
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    There was significantly reduced tumor necrosis factor-α mRNA expression in the aneurysm walls and CD68-positive cell infiltration in the aneurysm walls.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats, lixisenatide reduced aneurysm development on day 28.

    In plain wordsIn rats, lixisenatide reduced aneurysm development on day 28.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAneurysm development on day 28
    Study

    Ratn: not reported in source

    Abdominal aortic aneurysm
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    On day 28, it was evident that the lixisenatide had dramatically reduced aneurysm development in the rats.
    1 context sentence
    Summary · context
    Lixisenatide was injected subcutaneously 7 days after aneurysm preparation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.